Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893449 | 0.90 | EGLN1 (0.44) | KDM4CEGLN1FTOBBOX1KDM6B | |
| SCHEMBL5034433 | 0.80 | KDM4C (0.48) | KDM4CEGLN1FTOBBOX1KDM6B | |
| SCHEMBL3923469 | 0.78 | KDM4C (0.46) | KDM4CEGLN1FTOBBOX1KDM6B | |
| SCHEMBL4758413 | 0.77 | EGLN1 (0.48) | KDM4CEGLN1FTOBBOX1 | |
| SCHEMBL18496406 | 0.76 | EGLN1 (0.47) | KDM4CEGLN1FTOBBOX1KDM5B | |
| SCHEMBL522660 | 0.76 | EGLN1 (0.59) | EGLN1FTOBBOX1EGLN3HIF1AN | |
| SCHEMBL521900 | 0.76 | EGLN1 (0.66) | EGLN1FTOBBOX1KDM6BKDM5B | |
| SCHEMBL9265977 | 0.74 | MEN1 (0.44) | — | |
| SCHEMBL3364028 | 0.74 | FTO (0.46) | KDM4CEGLN1FTOEGFRLCK | |
| SCHEMBL521839 | 0.74 | EGLN1 (0.66) | EGLN1FTOBBOX1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007047194-A2 | METHODS FOR TREATING MITF-RELATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | KDM4C 4460/4885EGLN1 10/4885FTO 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.